What this is
- How it works
- How it works isn't classified yet
- Tested for
- OSA
- Main trialPhase 3
- “The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.”In the company’s words, NCT06566820 on ClinicalTrials.gov
- Other names
- Aroxybutynin and Atomoxetine
Other drugs for OSA
- RibupatideHengrui · Kailera · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- BofanglutideGan & Lee · Carnot Laboratories · Phase 3
- EcnoglutideSciwind Biosciences · Phase 3
- EloralintideEli Lilly · Phase 3
- HDM1005Huadong Medicine · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Enrolling by invitation | 30 Jun 2026 | Continuation Protocol for Obstructive Sleep Apnea (OSA) | |
| Phase 3Completed | 10 Mar 2025 | Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) | |
| Phase 3Completed | 7 May 2025 | Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) | |
| Phase 2Completed | 28 May 2021 | Crossover Trial of AD109 in Obstructive Sleep Apnea | |
| Phase 2Completed | 31 May 2021 | AD109 Dose Finding in Mild to Moderate OSA | |
| Phase 2Completed | 20 Jul 2022 | Parallel Arm Trial of AD109 and AD504 In Patients With OSA | |
| Phase 2Completed | 26 Dec 2024 | Study That Tests AD109 in Patients Taking GLP-1 Drugs |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026